Patent · US Active

Enhancer of zeste homolog 2 inhibitors

US9790212B2 · kind B2 · utility

1Cited by

8References

20Claims

0Family size

Assignee

GlaxoSmithKline Intellectual Property (No. 4) Limited · GB

Inventors

Charles William Blackledge, Jr. · Spring City, US
Joelle Lorraine Burgess · Collegeville, US
Neil W. Johnson · Collegeville, US
Jiri Kasparec · King of Prussia, US
Steven David Knight · West Chester, US
Louis Lafrance · Collegeville, US
Juan Luengo · Collegeville, US
William Henry Miller · Collegeville, US
Kenneth A. Newlander · West Chester, US
Stuart Paul Romeril · Collegeville, US
Mark Schulz · Skippack, US
Dai-Shi Su · New York, US
Xinrong Tian · Collegeville, US

Key dates

Filing date	Oct 13, 2016
Grant date	Oct 17, 2017
Priority date	—
Expiry date	Oct 13, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D413/14
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

This invention relates to novel compounds according to Formula (III)(a) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), and to pharmaceutical compositions containing them.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.